Molecular genetic and cytogenetic determinants of primary resistance or loss of the response to treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia

Journal Title: Медичні перспективи - Year 2015, Vol 20, Issue 3

Abstract

Aim of this study was to analyze molecular genetic and cytogenetic reasons for disease resistance to tyrosine kinase inhibitors (TKI) imatinib (IM) and nilotinib (NI) in patients with chronic myeloid leukemia (CML). Material and methods. A group of 32 CML patients with primary or acquired resistance to TKI treatment was investigated. Cytogenetic response was determined by conventional karyotyping with differential banding. Presence of BCR-ABL kinase domain mutations was investigated by direct sequencing. Results and discussion. The frequency of mutations was 37% (12 patients) with prevailing occurrence of mutations with low sensitivity to nilotinib – E255K/V; Т315I; F359V; Y253H. In 47% of the cases (15 patients) additional chromosome aberrations (ACA) were revealed which could also be the reason for TKI resistance in patients without BCR/ABL mutations. Patients with detected mutations of BCR/ABL gene were either switched to nilotinib or treated with increased dose of IM. Cytogenetic response was achieved in only 2 patients with mutations and in 12 patients without them. Frequency of blast crisis development did not differ significantly in both groups. Conclusions. Among the investigated patients with CML resistant to IM BCR/ABL gene mutations were detected in more than third of the cases whereas ACA were found in almost half of the group. Taking into account revealed prevalence of mutations not sensitive to the 2nd generation TKI nilotinib, investigation of mutational status has to be obligatory in all patients for whom treatment correction is considered. Presence of ACA should also be taken into account in patients requiring administration of the second line TKI since they can adversely influence expected treatment response as well.

Authors and Affiliations

K. Kotlyarchuk, Z. Maslyak, A. Lukianova, O. Tsyapka , I. Selina, H. Usenko

Keywords

Related Articles

Influence of inhalation anesthesia in caesarean section on parturients’ cognitive functions

General anaesthesia may be the cause of different damages of the nervous system after surgery. Anaesthesia technique may be preventive factor of developing or worsening postoperative cognitive disfunctions. A research ai...

Cytokine profile and efficacy of chemotherapy depending on thyroid state in patients with pulmonary tuberculosis

Objective of the study is definition of cytokine balance and the outcomes of chemotherapy of tuberculosis patients depending on their thyroid state. Materials and methods: 60 tuberculosis patients with pulmonary: 30 pers...

Identification of risk factors of computer information technologies in education

The basic direction of development of secondary school and vocational training is computer training of schoolchildren and students, including distance forms of education and widespread usage of world information systems....

Особливості клінічного оформлення шизофренії з коморбідними соматичними розладами

Особенности клинического оформления шизофрении с коморбидными соматическими рас­стройствами. Опря Е.В. С целью определения особенностей клинического оформления шизофрении, соче­танной с соматическими заболеваниями, обсле...

Morphologic and immune-histochemic peculiarities of placenta in its dysfunction in anemia of pregnancy

Placental dysfunction occurs in 17-35% of pregnant women. Iron deficiency anemia complicating pregnancy and childbirth affects fetal development. In its turn, pregnancy contributes to the rapid progress of iron deficienc...

Download PDF file
  • EP ID EP90058
  • DOI -
  • Views 129
  • Downloads 0

How To Cite

K. Kotlyarchuk, Z. Maslyak, A. Lukianova, O. Tsyapka, I. Selina, H. Usenko (2015). Molecular genetic and cytogenetic determinants of primary resistance or loss of the response to treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Медичні перспективи, 20(3), 67-73. https://www.europub.co.uk/articles/-A-90058